‘-Omics’ Data – So where is the signal, please?
Biology has over recent decades moved to finer and finer levels of details, be it… Read More »‘-Omics’ Data – So where is the signal, please?
Andreas Bender/Developing and applying novel data mining approaches of chemical and biological data, in drug discovery, chemical biology, and in silico toxicology/Reader at the Centre for Molecular Science Informatics of the University of Cambridge/Co-founder of Healx Ltd., for data-driven drug repurposing for rare diseases http://www.healx.io/Co-founder of PharmEnable Ltd., for accessing new chemistry for difficult targets http://www.pharmenable.com
Biology has over recent decades moved to finer and finer levels of details, be it… Read More »‘-Omics’ Data – So where is the signal, please?
The recent publication ‘Deep learning enables rapid identification of potent DDR1 kinase inhibitors‘ by the… Read More »So did ‘AI’ just discover its first drug? Comment on “Deep learning enables rapid identification of potent DDR1 kinase inhibitors”
‘All happy molecules are alike; each unhappy molecule is unhappy in its own way.’ Anna… Read More »‘AI’ in Toxicology (In Silico Toxicology) – The Pieces Don’t Yet Fit Together
Artificial Intelligence (AI) has been described as the ‘fourth industrial revolution’, that will lead us… Read More »Why AI and Drug Discovery are no match made in heaven
Machine Learning and Artificial Intelligence are increasing in importance currently – due to significantly increased… Read More »DrugDiscovery.NET – AI and Machine Learning in Drug Discovery, in Practice
Andreas Bender E-Mail: andreas AT drugdiscovery DOT net Web: http://andreasbender.de/ LinkedIn: https://www.linkedin.com/in/andreas-bender-1441441/ Twitter: https://twitter.com/AndreasBenderUK UK… Read More »Contact